NUFIP2

Across TCGA pan-cancer cohorts, NUFIP2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NUFIP2 data layer compared with 29 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NUFIP2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated NUFIP2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and UCEC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where NUFIP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.738	0.940	.001	30	view →
PDAC	OS	Quartile	All	0.341	0.690	<.001	21	view →
LUAD	DFS	Tertile	III,IV	0.905	0.479	.023	20	view →
UCEC	DFS	Median	III,IV	0.904	0.445	.037	4	view →
HNSC	DFS	Median	IV	0.673	0.850	.018	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NUFIP2–CCRCC (OS)

Open the CCRCC breakdown →